MiMedx reported mixed third-quarter trends: Surgical sales grew, while Wound Care remained pressured by Medicare reimbursement changes. The stock rose 0.5% after earnings, a roughly flat reaction.
Shares declined 2.1% following Q2 results and acquisition news as investors likely digested ongoing challenges in wound care despite surgical growth and the transformational Sanara MedTech deal.